Our data is supported by previous studies that linked the increase in ROS levels, after different therapies with inhibitors of the BRAF and MEK kinases, with ROS-induced resistance to treatments, in melanoma cells or in animal/patient tumors40,41. The gene discussed is MAP2K7; the disease is melanoma.